8-K: Harrow Acquires TYRVAYA Nasal Spray for Dry Eye

Harrow, Inc. has completed the acquisition of TYRVAYA (varenicline solution) nasal spray, a differentiated treatment for dry eye disease, from Viatris Inc., expanding its ocular surface franchise.

Summary

• Harrow, Inc. has finalized the acquisition of TYRVAYA (varenicline solution) nasal spray, a treatment for dry eye disease, from Viatris Inc.
• The acquisition grants Harrow worldwide rights to TYRVAYA, excluding Japan, where Viatris retains commercialization rights and will pay Harrow royalties.
• Harrow paid $30 million in cash at closing, funded by existing cash reserves.
• Additional contingent milestone payments of up to $70 million are possible, tied to net sales thresholds through December 31, 2029, for a potential total consideration of $100 million.
• TYRVAYA is the first and only FDA-approved nasal spray for dry eye disease, stimulating natural tear production.
• The acquisition includes new drug applications, regulatory approvals, intellectual property, technology, and inventory.
• Approximately 40 personnel from Viatris with expertise in TYRVAYA and the dry eye market are expected to join Harrow's commercial team in Q4 2026.
• Harrow anticipates TYRVAYA will generate over $30 million in revenue in 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strategic growth and expansion in a key therapeutic area.

Positives

• Acquisition of a differentiated, first-in-class nasal spray for dry eye disease (TYRVAYA).
• Expansion of Harrow's ocular surface franchise, complementing its existing VEVYE therapy.
• Strengthened market position in the large and growing U.S. dry eye market.
• Integration of approximately 40 experienced personnel from Viatris to bolster the commercial team.
• Expected revenue contribution of over $30 million from TYRVAYA in 2027.
• Synergistic commercial opportunities by offering two distinct dry eye treatments from a single provider.
• TYRVAYA has existing physician awareness, a prescription base, and real-world clinical experience.
• Viatris will pay Harrow tiered royalties on net sales of TYRVAYA in Japan.

Negatives

• Potential for up to $70 million in contingent milestone payments, increasing the total acquisition cost if sales targets are met.
• Viatris retains rights to Japan, limiting global exclusivity for TYRVAYA.
• The acquisition is funded by cash on hand, potentially impacting liquidity for other initiatives.
• Integration of new personnel and commercial operations may present execution risks.

Risks

• Actual results may differ materially from forward-looking statements regarding milestone payments and future sales.
• Competition from other pharmaceutical companies in the dry eye market.
• Regulatory and legal risks associated with pharmaceutical operations.
• Potential challenges in integrating the acquired assets and personnel.
• Market acceptance and physician adoption of TYRVAYA alongside VEVYE.
• Reliance on specialty pharmacy partners like PhilRx for distribution.
• General economic and business conditions, including inflation and supply chain challenges.

Future Outlook

Harrow anticipates TYRVAYA to contribute over $30 million in revenue in 2027, leveraging its established prescription base, physician awareness, and experienced commercial team, combined with Harrow's dedicated Ocular Surface infrastructure. The company also expects to negotiate a collaboration agreement with Viatris for TYRVAYA in Japan and receive tiered royalties on net sales there.

Management Comments

• "Today marks an important step forward for Harrow and for the physicians and patients we serve. Dry eye disease is complex and multifactorial, and there is no single treatment approach that works for every patient. VEVYE and TYRVAYA approach dry eye differently and give eyecare professionals two distinct tools from one organization committed to serving this market. VEVYE remains the cornerstone of our dry eye franchise, while TYRVAYA gives us an established, complementary prescription brand with a unique route of administration and an existing base of physicians who know and use the product."
• "We see a significant commercial opportunity ahead. TYRVAYA comes to Harrow with meaningful physician awareness, an established prescription base, and years of real-world clinical experience. By combining that foundation with Harrow's expanding Ocular Surface commercial organization, market access capabilities, and focus on patient access and affordability, we believe we can introduce TYRVAYA to many more eyecare professionals and patients while also expanding awareness of VEVYE among existing TYRVAYA prescribers."

Industry Context

StockSavvy.ai notes that this acquisition aligns with industry trends of consolidation and portfolio expansion in the ophthalmology sector, particularly in the lucrative dry eye disease market. By acquiring TYRVAYA, Harrow strengthens its competitive position against other players offering specialized treatments for ocular surface conditions.

Comparison to Industry Standards

• The acquisition price of up to $100 million for TYRVAYA, a differentiated dry eye treatment, appears within the typical range for such assets in the pharmaceutical industry, considering its FDA approval and unique nasal spray delivery mechanism.
• Harrow's projected 2027 revenue of over $30 million for TYRVAYA suggests an expectation of significant market penetration, which would need to be benchmarked against the sales performance of comparable dry eye treatments like Restasis, Xiidra, or even Harrow's own VEVYE.
• The integration of approximately 40 sales personnel from Viatris is a common strategy to ensure commercial success post-acquisition, aiming to leverage existing relationships and market knowledge, a practice seen in numerous pharmaceutical M&A deals.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market share, leading to enhanced shareholder value, but also contingent liabilities for milestone payments.
• Patients: Access to a differentiated, drop-free treatment option for dry eye disease, potentially improving treatment adherence and outcomes.
• Eyecare Professionals: Expanded treatment options with two distinct dry eye therapies (VEVYE and TYRVAYA) from a single provider, allowing for more personalized patient care.
• Suppliers: Potential for increased demand for related services and materials if TYRVAYA sales grow significantly.

Next Steps

• Onboard approximately 40 personnel from Viatris during the fourth quarter of 2026.
• Integrate TYRVAYA into Harrow's Ocular Surface commercial organization.
• Negotiate a collaboration or similar agreement with Viatris for TYRVAYA in Japan.
• Begin commercialization of TYRVAYA through Harrow's commercial organization immediately after closing.
• File the Purchase Agreement as an exhibit to Harrow's Quarterly Report on Form 10-Q for the period ended September 30, 2026.

Key Dates

Recommendation

The acquisition of TYRVAYA is a strategically sound move that strengthens Harrow's position in the dry eye market and offers significant growth potential. However, the substantial contingent liabilities and the need for successful integration and commercial execution warrant a 'hold' rating until the company demonstrates sustained revenue growth and profitability from this acquisition. Further monitoring of sales performance and milestone achievement is advised.

Keywords

Dry Eye Disease, TYRVAYA, Viatris, Ophthalmic, Nasal Spray, Acquisition, Varenicline Solution, VEVYE